Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 1407 citing articles:

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll
Cancer Cell (2015) Vol. 27, Iss. 4, pp. 450-461
Open Access | Times Cited: 3733
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 651-668
Open Access | Times Cited: 3206
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 17, pp. 1714-1768
Open Access | Times Cited: 3153
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok
Journal of Clinical Oncology (2015) Vol. 33, Iss. 17, pp. 1974-1982
Open Access | Times Cited: 2437
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma, James P. Allison
Cell (2015) Vol. 161, Iss. 2, pp. 205-214
Open Access | Times Cited: 2092
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Jean‐Marie Michot, Camille Bigenwald, Stéphane Champiat, et al.
European Journal of Cancer (2016) Vol. 54, pp. 139-148
Closed Access | Times Cited: 1926
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov, Adi Diab, K. Abdallah, et al.
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 1713
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona, Eleftherios P. Diamandis, Ivan M. Blasutig
BMC Medicine (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 1071
Therapeutic Targeting of the Tumor Microenvironment
Leire Bejarano, Marta Joana Costa Jordão, Johanna A. Joyce
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 933-959
Open Access | Times Cited: 1071
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1020
CTLA-4: a moving target in immunotherapy
Behzad Rowshanravan, Neil Halliday, David M. Sansom
Blood (2017) Vol. 131, Iss. 1, pp. 58-67
Open Access | Times Cited: 967
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros, Ahmad A. Tarhini, Émilie Routier, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 8, pp. 473-486
Closed Access | Times Cited: 947
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum, Hua Liang, Liufu Deng, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 6, pp. 365-379
Closed Access | Times Cited: 880
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan, Burles A. Johnson, Eric R. Lutz, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 4, pp. 209-222
Open Access | Times Cited: 880
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H.C. Baumeister, Gordon J. Freeman, Glenn Dranoff, et al.
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 539-573
Closed Access | Times Cited: 835
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain, Stefan Diem, James Larkin
Cancer Treatment Reviews (2016) Vol. 44, pp. 51-60
Closed Access | Times Cited: 799
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi, Michael Lim, Theodore L. DeWeese, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 13, pp. e498-e509
Closed Access | Times Cited: 772
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 6, pp. 737-746
Closed Access | Times Cited: 772
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, et al.
Journal of Clinical Oncology (2016) Vol. 35, Iss. 1, pp. 40-47
Closed Access | Times Cited: 685
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 6, pp. 311-335
Open Access | Times Cited: 671
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Christopher Groth, Xiaoying Hu, Rebekka Weber, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 1, pp. 16-25
Open Access | Times Cited: 664
Genetics and biology of prostate cancer
Guocan Wang, Di Zhao, Denise J. Spring, et al.
Genes & Development (2018) Vol. 32, Iss. 17-18, pp. 1105-1140
Open Access | Times Cited: 634
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero, David M. Berman, M. Ángela Aznar, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 8, pp. 457-472
Closed Access | Times Cited: 600
Treatment of Advanced Prostate Cancer
Min Yuen Teo, Dana E. Rathkopf, Philip W. Kantoff
Annual Review of Medicine (2019) Vol. 70, Iss. 1, pp. 479-499
Open Access | Times Cited: 592
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 5, pp. 395-405
Open Access | Times Cited: 577
Page 1 - Next Page

Scroll to top